News and Announcements
Universal Biosensors Appoints David Hoey as Non-Executive Director
- Published March 02, 2016 3:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
2nd March 2016, ASX Announcement
Universal Biosensors, Inc. (ASX: UBI) today announced the appointment of Mr. David Hoey as an independent non-executive director to the Board of Universal Biosensors (UBI). This appointment forms part of the board renewal process which has occurred over recent years.
Mr. Hoey has more than 25 years’ experience in technology financing and commercialization. David is a US-based director and his primary expertise is in business development, strategic planning, market development, corporate partnering and financings for medical technologies, diagnostics and drug development.
David is currently the chief executive officer and a director of Vaxxas Pty Ltd, a Brisbane-based company that is developing and commercializing a novel vaccine delivery technology – the Nanopatch™.
To read the full announcement, please click here.
Company Updates
Beyond Strategy: Why Your Network Will Define Your Business Exit
Beyond operational readiness, a strong, purpose-built network is crucial for a successful business exit. Learn how an “exit ecosystem” of advisors, capital partners, and fellow founders can define the outcome of your most significant transaction.
Australia’s Trillion-Dollar Defence Tech Boom: A Call to Action for Founders
The global defence technology landscape is no longer a niche for the select few. For Australian founders, it represents a monumental, yet frequently underestimated, investment opportunity. Fuelled by escalating geopolitical tensions and a fundamental re-prioritisation of global spending, this sector is experiencing an unprecedented tailwind. According to Steve Baxter, Lead Investor at Beaten Zone Venture […]
IPO Bound: The Strategic Edge Guiding Australian Investors to India’s Next Unicorns
Uncover Creek Partners’ strategic vision for Australian investors in India’s booming economy. From IPO-bound deals to pioneering tech exchange, this playbook reveals how to navigate and profit from a market set to hit $7 trillion.
Backed By Leading Investment Groups and Family Offices
